Interferons as components of the complex web of reactions sustaining inflammation in idiopathic inflammatory myopathies

Cytokine

Volumn 74, Issue 1, 2015, Pages 81-87

  De Paepe, Boel ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Chemokines; Cytokines; Inflammatory myopathy; Interferon inducible genes; Interferons

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERFERON; MYXOVIRUS RESISTANCE PROTEIN; RNA HELICASE; CYTOKINE;

ARTICLE; DERMATOMYOSITIS; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; INTRACELLULAR SIGNALING; LYMPHOCYTE FUNCTION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR PATHOLOGY; MYOSITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN TARGETING; T LYMPHOCYTE; UPREGULATION; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MUSCLE; PATHOLOGY;

ANIMALS; CYTOKINES; DERMATOMYOSITIS; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INTERFERON TYPE I; INTERFERONS; MAJOR HISTOCOMPATIBILITY COMPLEX; MUSCLES; MYOSITIS;

EID: 84930186815     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.10.012     Document Type: Article

References (76)

1. Dalakas M.C. Pathogenesis and therapies of immune-mediated myopathies. Autoimmun Rev 2011, 11:203-206.
2. Siegal F.P., Kadowaki N., Shodell M., Fitzgerald-Bocarsly P.A., Shah K. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999, 284:1835-1837.
3. Schneider W.M., Dittmann Chevillotte M., Rice C.M. Interferon-stimulated genes: a complex web of host defenses. Ann Rev Immunol 2014, 32:513-545.
4. Cappelletti C., Baggi F., Zolezzi F., Biancolini D., Beretta O., Severa M., et al. Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies. Neurology 2011, 76:2079-2088.
5. Dietrich L.L., Bridges A.J., Albertini M.R. Dermatomyositis after interferon alpha treatment. Med Oncol 2000, 17:64-69.
6. Stubgen J.P. Interferon alpha and neuromuscular disorders. J Neuroimmunol 2009, 207:3-17.
7. Somani A.K., Swick A.R., Cooper K.D., McCormick T.S. Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling. Arch Dermatol 2008, 144:1341-1349.
8. Greenberg S.A., Pinkus J.L., Pinkus G.S., Burleson T., Sanoudou D., Twail R., et al. Interferon-α/β-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005, 57:664-678.
9. Niewold T.B., Kariuki S.N., Morgan G.A., Shrestha S., Pachman L.M. Elevated serum interferon-α activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy. Arthr Rheum 2009, 60:1815-1824.
10. Horai Y., Koga T., Fujikawa K., Takatani A., Nishino A., Nakashima Y., et al. Serum interferon-α is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis. Mod Rheumatol 2014, 10.3109/14397595.2014.900843.
11. Eloranta M.L., Barbasso Helmers S., Ulfgren A.K., Ronnblom L., Alm G.V., Lundberg I.E. A possible mechanism for endogenous activation of the type 1 interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/Anti-Ro 60 autoantibodies. Arthr Rheum 2007, 56:3112-3124.
12. Balboni I., Niewold T.B., Morgan G., Limb C., Eloranta M.L., Ronnblom L., et al. Interferon-α induction and detection of anti-Ro, anti-La, anti-Sm, and anti-RNP autoantibodies by autoantigen microarray analysis in juvenile dermatomyositis. Arthr Rheum 2013, 65:2424-2429.
13. Liao A.P., Salajegheh M., Nazareno R., Kagan J.C., Jubin R.G., Greenberg S.A. Interferon beta is associated with type 1 interferon-inducible gene expression in dermatomyositis. Ann Rheum Dis 2011, 70:831-836.
14. Schmidt J., Barthel K., Wrede A., Salajegheh M., Bahr M., Dalakas M.C. Interrelation of inflammation and APP in sIBM: IL-1 β induces accumulation of β-amyloid in skeletal muscle. Brain 2008, 131:1228-1240.
15. Tezak Z., Hoffman E.P., Lutz J.L., Fedczyna T.O., Stephan D., Bremer E.G., et al. Gene expression profiling in DQA1*0501+children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol 2002, 168:4154-4163.
16. Allenbach Y., Chaara W., Rosenzwajg M., Six A., Prevel N., Mingozzi F., et al. Th1 response and systemic Treg deficiency in inclusion body myositis. PLoS One 2014, 9:e88788.
17. Baird G.S., Montine T.J. Multiplex immunoassay analysis of cytokines in idiopathic inflammatory myopathy. Arch Pathol Lab Med 2008, 132:232-238.
18. Dastmalchi M., Grundtman C., Alexanderson H., Mavragani C.P., Einarsdottir H., Barbasso Helmers S., et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008, 67:1670-1677.
19. Preuse C., Goebel H.H., Held J., Wengert O., Scheibe F., Irlbacher K., et al. Immune-mediated necrotizing myopathy is characterized by a specific Th1-M1 polarized immune profile. Am J Pathol 2012, 181:2161-2171.
20. Lundberg I., Ulfgren A.K., Nyberg P., Andersson U., Klareskog L. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthr Rheum 1997, 40:865-874.
21. Ivanidze J., Hoffmann R., Lochmuller H., Engel A.G., Hohlfeld R., Dornmair K. Laser microdissection reveals differential up-regulation of IFN-γ signaling cascade in attacked versus nonattacked myofibers. Am J Pathol 2011, 179:1347-1358.
22. Chinoy H., Salway F., John S., Fertig N., Tait B.D., Oddis C.V., et al. Interferon-gamma and interleukin-4 gene polymorphisms in Caucasian idiopathic inflammatory myopathy patients in UK. Ann Rheum Dis 2007, 66:937-970.
23. Samarajiwa S.A., Forster S., Auchetti K., Hertzog P.J. INTERFEROME: the database of interferon regulated genes. Nucl Acids Res 2008, 37:852-857.
24. Greenberg S.A., Higgs B.W., Morehouse C., Walsh R.J., Kong S.W., Brohawn P., et al. Relationship between disease activity and type 1 interferon-and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis. Genes Immun 2012, 13:207-213.
25. Salajegheh M., Kong S.W., Pinkus J.L., Walsh R.I., Liao A., Nazareno R., et al. Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy. Ann Neurol 2010, 67:53-63.
26. Suarez-Calvet X., Gallardo E., Nogales-Gadea G., Querol L., Navas M., Diaz-Manera J., et al. Altered RIG-I/DDX58-mediated innate immunity in dermatomyositis. J Pathol 2014, 5:258-268.
27. McDouall R.M., Dunn M.J., Dubowitz Expression of class I and class II MHC antigens in neuromuscular diseases. J Neurol Sci 1989, 89:213-226.
28. Isenberg D.A., Rowe D.J., Shearer M., Nivick D., Beverley P.C. Localization of IFN and interleukin 2 in polymyositis and muscular dystrophy. Clin Exp Immunol 1986, 63:450-458.
29. Das L., Blumbergs P.C., Manavis J., Limaye V.S. Major histocompatibility complex class I and II expression in idiopathic inflammatory myopathy. Appl Immunohistochem Mol Morphol 2013, 21:539-542.
30. Rodriguez Cruz P.M., Luo Y.B., Miller J., Junckerstorff R.C., Mastaglia F.L., Fabian V. An analysis of the sensitivity and specificity of MHC-I and MHC-II immunohistochemical staining in muscle biopsies for the diagnosis of inflammatory myopathies. Neuromuscul Disord 2014, 10.1016/j.nmd.2014.06.436.
31. Shimizu J., Kawai M., Kanazawa I. Sarcolemmal coexpression of intercellular adhesion molecule-1 (ICAM-1) and HLA-DR in inflammatory myopathy. Neuropathol 2007, 14:149-157.
32. Englund P., Lindroos E., Nennesmo I., Klareskog L., Lundberg I.E. Skeletal muscle fibres express major histocompatibility complex class II antigens independently of inflammatory infiltrates in inflammatory myopathies. Am J Pathol 2001, 159:1263-1273.
33. Michaelis D., Goebels N., Hohlfeld R. Constitutive and cytokine-induced expression of human leukocyte antigens and cell adhesion molecules by human myotubes. Am J Pathol 1993, 143:1142-1149.
34. Inukai A., Kuru S., Liang Y., Takano A., Kobayashi Y., Sakai M., et al. Expression of HLA-DR and its enhancing molecules in muscle fibres in polymyositis. Muscle Nerve 2000, 23:385-392.
35. Michaelis D., Goebels N., Hohlfeld R. Constitutive and cytokine-induced expression of human leukocyte antigens and cell adhesion molecules by human myotubes. Am J Pathol 1993, 143:1142-1149.
36. Airo P., Ghidini C., Zanotti C., Scarsi M., Cattaneo R., Caimi L., et al. Upregulation of myxovirus-resistance protein A: a possible marker of type I interferon induction in systemic sclerosis. J Rheumatol 2008, 35:2192-2200.
37. Walsh R.J., Kong S.W., Yao Y., Jallal B., Kiener P.A., Pinkus J.L., et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthr Rheum 2007, 56:3784-3792.
38. O'Connor K.A., Abbott K.A., Sabin B., Kuroda M., Pachman L.M. MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement. Clin Immunol 2006, 120:319-325.
39. Trinchieri G. Type I interferon: friend of foe?. J Exp Med 2010, 207:2053-2063.
40. Platanias L.C. Mechanisms of type-I-and type-II-interferon-mediated signalling. Nat Rev 2005, 5:375-386.
41. Taniguchi T., Ogasawara K., Takaoka A., Tanaka N. IRF family of transcription factors as regulators of host defense. Ann Rev Immunol 2001, 19:623-655.
42. Reder A.T., Feng X. Aberrant type I interferon regulation in autoimmunity: opposite directions in MS and SLE, shaped by evolution and body ecology. Front Immunol 2013, 4:e281.
43. Sun W.C., Sun Y.C., Yan B., Shi G.X. Dysregulation of the type 1 interferon system in adult-onset clinically amyopathic dermatomyositis has a potential contribution to the development of interstitial lung disease. Br J Dermatol 2012, 167:1236-1244.
44. Bogunovic D., Boisson-Dupuis S., Casanova J.L. ISG15: leading a double life as a secreted molecule. Exp Mol Med 2013, 45:e18.
45. Greenberg S.A. Type 1 interferons and myositis. Arthr Res Ther 2010, 12:S4.
46. Diamond M.S., Frazan M. The broad-spectrum antiviral functions of IFIT and IFITM proteins. Nat Rev Immunol 2013, 13(1):46-57.
47. Sato S., Hoshino K., Satoh T., Fujita T., Kawakami Y., Fujita T., et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major auto antigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthr Rheum 2009, 60:2193-2200.
48. Cen H., Wang W., Leng R.X., Wang T.Y., Pan H.F., Fan Y.G., et al. Association of IFIH1 rs1990760 polymorphism with susceptibility to autoimmune diseases: a meta-analysis. Autoimmunity 2013, 46:455-462.
49. Allenbach Y., Leroux G., Rigolet A., Hervier B., Hie M., Limal N., et al. MDA-5 associated myositis: towards a molecular and morphological definition of a distinct entity. J Neuromusc Dis 2014, 1:S256.
50. McLoughlin R.M., Witowski J., Robson R.L., Wilkinson T.S., Hurst S.M., Williams A.S., et al. Interplay between IFN-γ and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation. J Clin Invest 2003, 112:598-607.
51. Bilgic H., Ytterberg S.R., Amin S., McNallan K.T., Wilson J.C., Koeuth T., et al. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthr Rheum 2009, 60:3436-3446.
52. Laver T., Nozell S.E. Benveniste EN (2008) IFN-β -mediated inhibition of IL-8 expression requires the ISGF3 components Stat1, Stat2, and IRF-9. J Interferon Cytok Res 2008, 28:13-23.
53. Tominaga K., Yoshimoto T., Torigoe K., Kurimoto M., Matsui K., Hada T., et al. IL-12 synergizes with IL-18 or IL-1 β for IFN-γ production from human T cells. Int Immunol 2000, 12:151-160.
54. Tucci M., Quatraro C., Dammacco F., Silvestris F. Interleukin-18 overexpression as a hallmark of the activity of autoimmune inflammatory myopathies. Clin Exp Immunol 2006, 146:21-31.
55. Boule M.W., Broughton C., Mackay F., Akira S., Marshak-Rothstein A., Rifkin I.R. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med 2004, 199:1631-1640.
56. Woo S.J., Im J., Jeon J.H., Kang S.S., Lee M.H., Yun C.H., et al. Induction of BAFF expression by IFN-γ via JAK/STAT signaling pathways in human intestinal epithelial cells. J Leukocyte Biol 2013, 93:363-368.
57. Baek A., Park H.J., Na S.J., Shim D.S., Moon J.S., Yang Y., et al. The expression of BAFF in the muscles of patients with dermatomyositis. J Neuroimmunol 2012, 249:96-100.
58. Rani M.R.S., Shrock J., Appachi S., Rudick R.A., Williams B.R.G., Ransohoff R.M. Novel interferon-β -induced gene expression in peripheral blood cells. J Leukocyte Biol 2007, 82:1353-1360.
59. De Rossi M., Bernasconi P., Baggi F., de Waal Malefyt R., Mantegazza R. Cytokines and chemokines are both expressed by human myoblasts: possible relevance for the immune pathogenesis of muscle inflammation. Int Immunol 2000, 12:1329-1335.
60. Antonelli A., Ferrari S.M., Fallahi P., Ghiri E., Crescioli C., Romagnani P., et al. Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: modulation by peroxisome proliferator-activated receptor-gamma agonists. Cytokine 2010, 50:260-267.
61. De Paepe B., De Keyzer K., Martin J.J., De Bleecker J.L. Alpha-chemokine receptors CXCR1-3 and their ligands in idiopathic inflammatory myopathies. Acta Neuropathol 2005, 109:576-582.
62. Fall N., Bove K.E., Stringer K., Lovell D.J., Brunner H.I., Weiss J., et al. Association between lack of angiogenic response in muscle tissue and high expression of angiostatic ELR-negative CXC chemokines in patients with juvenile dermatomyositis: possible link to vasculopathy. Arthr Rheum 2005, 52:3175-3180.
63. Conrady C.D., Zheng M., Mandal N.A., van Rooijen N., Carr D.J.J. IFN-α -driven CCL2 production recruits inflammatory monocytes to infection site in mice. Mucosal Immunol 2013, 6:45-55.
64. Bug G., Aman M.J., Tretter T., Huber C., Peschel C. Induction of macrophage-inflammatory protein 1 alpha (MIP-1alpha) by interferon-alpha. Exp Hematol 1998, 26:117-123.
65. De Bleecker J.L., De Paepe B., Vanwalleghem I.E., Schroeder J.M. Differential expression of chemokines in inflammatory myopathies. Neurology 2002, 58:1779-1785.
66. De Paepe B., Creus K.K., De Bleecker J.L. Role of cytokines and chemokines in idiopathic inflammatory myopathies. Curr Opin Rheumatol 2009, 21:610-616.
67. Guo X., Higgs B.W., Rebelatto M., Zhu W., Greth W., Yao Y., et al. Suppression of soluble T cell-associated proteins by an anti-interferon-α monoclonal antibody in adult patients with dermatomyositis or polymyositis. Rheumatology 2014, 53:686-695.
68. Kamijo R., Harada H., Matsuyama T., Bosland M., Gerecitano J., Shapiro D., et al. Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science 1994, 18:1612-1615.
69. De Paepe B., Racz G.Z., Schroeder J.M., De Bleecker J.L. Expression and distribution of the nitric oxide synthases in idiopathic inflammatory myopathies. Acta Neuropathol 2004, 108:37-42.
70. Stenzel W., Goebel H.H., Aronica E. Immune-mediated necrotizing myopathies - a heterogeneous group of diseases with specific myopathological features. Neuropathol Appl Neurobiol 2012, 38:632-646.
71. Schmidt J., Barthel K., Zschuentzsch J., Muth I.E., Swindle E.J., Hombach A., et al. Nitric oxide stress in sporadic inclusion body myositis muscle fibres: inhibition of inducible nitric oxide synthase presents interleukin-1 β-induced accumulation of β-amyloid and cell death. Brain 2012, 135:1102-1114.
72. D'Antona G., Mascaro A., Monopoli A., Miglietta D., Ongini E., Bottinelli R. Nitric oxide prevents atorvastatin-induced skeletal muscle dysfunction and alterations in mice. Muscle Nerve 2013, 47:72-80.
73. Trichieri G. IL-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994, 84:4008-4027.
74. Cruz A., Khader S.A., Torrado E., Fraga A., Pearl J.E., Pedrosa J., et al. Cutting edge: IFN-gamma regulates the induction and expansion of IL-17-producing CD4 T cells during mycobacterial infection. J Immunol 2006, 177:1416-1420.
75. Shen H., Xia L., Lu J., Xiao W. Interleukin-17 and interleukin-23 in patients with polymyositis and dermatomyositis. Scand J Rheumatol 2011, 40:217-220.
76. Higgs B.W., Zhu W., Morehouse C., White W.I., Brohawn P., Guo X., et al. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralization of a type 1 IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis 2014, 73:256-262.